top of page

【#ARTICLES|#Biomed】 BioXcel Therapeutics Announces FDA Approval of #IGALMI™

Writer's picture: ACC TMUACC TMU

對於精神分裂相關疾病困擾提供助益 “There are large numbers of patients who experience agitation associated with schizophrenia and bipolar disorders, and this condition has been a long-standing challenge for healthcare professionals to treat”

多了另一種治療的選擇 “The approval of #IGALMI, a self-administered film with a desirable onset of action, represents a milestone moment. It provides healthcare teams with an innovative tool to help control agitation. As clinicians, we welcome this much-needed new oral treatment option.”



 

4 views0 comments

Comments


Subscription

Want to receive the latest information on innovation and entrepreneurship in the biomedical industry? Subscribe us, and we will send the latest accelerator news.

Contact

Want to join the accelerator program? Need clinical collaboration resources? Commercialization of biomedical products and services? Feel free to contact us with an application.

TMUACC Logo-Final Version-2-08.png
bottom of page